Our Mission
With a dedicated team of scientists, researchers, and medical professionals, we are committed to advancing the field of bioscience diagnostics for chronic wounds. Our focus on innovation, precision, and patient-centric solutions drives us to create reliable and efficient products that meet the evolving needs of healthcare providers and patients.
Our Products & Services
-
Molecular Sequencing Technology
Our Sequencing technology is not subject to panel limitations, identifying aerobic and anaerobic bacteria, yeasts, bacteriophages, and resistance genes directly from wound swabs. We address the complexity and diversity of microbial environments within wounds.
-
Antibiotic Resistance Detection
Our innovative approach detects and links antibiotic resistance genes to specific microorganisms present in the wound. It provides actionable information on the predicted response of pathogens to various antibiotics, providing more valuable data for medical providers.
-
CHART
Sophisticated data querying to support targeted studies and data analysis. Correlate diverse data sets, presenting them in heat map visualizations to clarify patterns and associations. Advanced tools for statistical analysis and algorithms for deep data correlation assessment.
-
Clinical Data Collection
By integrating extensive clinical data, we're able to profile pathogen populations in biofilms, thus correlating pathogen populations with various clinical outcomes. Refine clinical reports and improve treatment recommendations based on real-world results.
Who We Work With
-
Medical practitioners specializing in chronic wounds, such as diabetic ulcers or pressure sores, who require detailed pathogen profiling to optimize treatment plans.
-
Institutions needing rapid and thorough identification of pathogens to treat infections effectively and prevent hospital-acquired infections (HAIs).
-
Facilities managing elderly or immuno-compromised patients, where wound management is a recurring challenge.
-
Entities focusing on microbial research, infectious diseases, and the development of novel antimicrobial treatments.
-
Firms engaged in creating new antibiotics or therapies for resistant strains, which could benefit from our detailed resistance gene mapping.